Pancreatic cancer is one of the hardest cancers to image well, and it is honest to say so at the start.
The pancreas sits deep in the abdomen, wrapped around major blood vessels. Tumours there are often surrounded by dense fibrous tissue that behaves differently from the cancer itself. Inflammation of the pancreas — pancreatitis — can look remarkably similar to malignancy on a scan. And a significant proportion of patients have obstruction, stents or recent procedures that further complicate what an image shows.
This guide explains what a PET CT adds in pancreatic cancer and what it does not, why CT remains the primary staging test rather than PET, the specific problem of distinguishing pancreatitis from cancer, why FAPI has emerged as a useful alternative tracer here, and how to prepare when jaundice, stents or diabetes are part of the picture.
Why CT, not PET, is the primary staging test
This surprises patients who assume PET is always the more advanced option. In pancreatic cancer it is not the first question asked.
The decision that dominates early management is whether the tumour can be surgically removed. That depends almost entirely on its relationship to the major blood vessels that run through and around the pancreas — the superior mesenteric artery and vein, the coeliac axis, the portal vein.
How much of a vessel’s circumference the tumour touches, whether it deforms it, whether there is a clear plane between them — these are millimetre questions about anatomy. They are answered by a dedicated pancreatic protocol CT, which is a multiphasic contrast study timed specifically to show the pancreas and those vessels at their clearest.
PET cannot resolve vessel involvement. It assesses metabolic activity, not tissue planes. So a pancreatic protocol CT is the primary staging test, and a PET is used to answer different questions alongside it.
If your surgeon has ordered a triphasic or pancreatic protocol CT and not a PET, that is standard practice rather than an omission.
Where PET does add value
1. Detecting distant disease before major surgery
This is the main use, and the reasoning matches other cancers where surgery is demanding.
Pancreatic surgery — the Whipple procedure in particular — is among the largest operations in general surgery, with a substantial recovery. It is undertaken with curative intent. If disease has already spread to the liver, the peritoneum or distant nodes, the operation cannot achieve that.
A whole-body PET performed before surgery can identify distant disease that a CT of the abdomen alone has not shown. Finding it changes the plan — which is the point.
2. Resolving equivocal findings
An indeterminate liver lesion, an uncertain node, a soft tissue area of unclear significance. A functional assessment can help settle whether it is likely to be disease.
3. Suspected recurrence after surgery
After a Whipple procedure, the anatomy is substantially rearranged and post-surgical change is extensive. Distinguishing scar from recurrent disease on CT alone is difficult. PET assesses activity rather than structure, which helps.
4. Assessing response to treatment
Particularly where chemotherapy is being given to shrink a borderline tumour with the hope of making surgery possible.
The hardest problem: pancreatitis versus cancer
This deserves its own section because it causes more diagnostic difficulty in the pancreas than anywhere else.
Chronic pancreatitis takes up FDG. So does an acute inflammatory episode. Autoimmune pancreatitis in particular can produce a mass-like appearance with intense uptake that closely resembles cancer.
The consequence is that a bright area in the pancreas does not by itself establish malignancy, and a mass with modest uptake does not exclude it.
This is why:
- Tissue diagnosis matters. EUS-guided sampling or image-guided biopsy is frequently required before treatment decisions, and a PET showing uptake does not remove that need.
- Your history matters enormously. Alcohol use, previous pancreatitis episodes, gallstone disease, autoimmune conditions — all change how a scan is read. Tell the centre.
- Old scans matter. A pancreatic abnormality present and unchanged for years reads very differently from one that appeared in six months.
Why FAPI is relevant in pancreatic cancer
This is where a genuinely useful development applies, and it is worth understanding.
Pancreatic ductal adenocarcinoma is characterised by an unusually dense stroma — the fibrous tissue surrounding and supporting the tumour cells. In many pancreatic tumours, the cancer cells themselves make up a relatively small proportion of the mass, with the rest being this reactive fibrous tissue.
FDG targets glucose consumption by cells. In a tumour where cellular density is low and stroma dominates, FDG uptake can be modest relative to the size and seriousness of the disease.
FAPI works differently. It targets fibroblast activation protein, which is expressed by the cancer-associated fibroblasts in that stroma. In other words, it targets the very tissue that makes pancreatic tumours difficult for FDG.
FAPI also has a practical advantage in the abdomen: normal liver and bowel show relatively low FAPI uptake, whereas both can be metabolically busy on FDG. That difference in background matters when you are looking for liver deposits or peritoneal disease.
FAPI is not a replacement for FDG in every patient, and the decision belongs to your treating team. But if your oncologist has requested a FAPI study rather than FDG, this is why.
The availability problem, and why it matters to you
FAPI is built on Gallium-68, which has a half-life of roughly 68 minutes. It cannot be manufactured at a distant facility and shipped, because most of it decays in transit. It must be produced close to the patient, on the day, from a generator.
This is why many centres offer FAPI only on particular days, when a supply has been arranged from outside — and why patients are sometimes told to wait.
Neurad has an in-house 68Ga generator, so FAPI, DOTANOC, PSMA, Exendin and Trivehexin studies are produced on site and scheduled on working days rather than held until an outside supply arrives.
Pancreatic neuroendocrine tumours are a different disease
An important distinction that patients sometimes miss.
Not every tumour in the pancreas is pancreatic ductal adenocarcinoma. Pancreatic neuroendocrine tumours are a separate group with different behaviour, different treatment and different imaging.
Well-differentiated neuroendocrine tumours typically express somatostatin receptors, which is what DOTANOC targets. A DOTANOC scan is generally the appropriate study for these, not FDG — and it also assesses suitability for PRRT.
Sometimes both DOTANOC and FDG are requested deliberately, because the combination tells the team something about tumour behaviour that neither alone conveys.
Insulinoma is a further special case: these are often very small and difficult to localise, and Exendin is the specialised study used for that purpose.
If your prescription names DOTANOC or Exendin rather than FDG, the tumour type is why — and substituting a cheaper or more available tracer means paying for a scan that cannot answer the question.
Preparation — with jaundice, stents and diabetes in mind
Standard FDG preparation applies, but pancreatic patients frequently have complications that need planning.
Diabetes and new-onset diabetes
Diabetes is common in pancreatic disease, and new-onset diabetes is sometimes the first sign of a pancreatic tumour. Blood sugar control may also be unstable.
This matters directly: circulating glucose competes with FDG, and poorly controlled sugar degrades image quality. Tell the centre you are diabetic at booking, say what you take and when, and ask how to handle it on the morning. Do not skip medication on your own initiative.
Jaundice and biliary stents
Many patients have obstructive jaundice, and many have had a stent placed to relieve it. Both are relevant.
Stent placement causes local inflammation that takes up the tracer. Cholangitis — infection in the biliary system — produces intense uptake. Always mention a stent and the date it was placed, and mention any fever or chills.
Poor appetite and weight loss
Many pancreatic patients are eating very little. Standard six-hour fasting instructions assume normal intake. If you have been eating poorly, say so — dehydration and low blood sugar behave differently in that situation.
Pancreatic enzyme supplements
Mention them if you take them.
Pain and lying flat
Pancreatic pain, particularly back pain, can make lying still for the acquisition difficult. Tell the centre before you are positioned rather than enduring it — adjustments are possible and discomfort causes movement.
Tell the centre these things when you book
- Whether you are diabetic, including new-onset diabetes, and what you take
- Whether you are jaundiced and whether a stent has been placed, and when
- Any fever, chills or suspected cholangitis
- Any history of pancreatitis, acute or chronic, and any alcohol history
- The date of any ERCP, EUS, biopsy or surgery
- The dates of any chemotherapy or radiotherapy
- How much you are eating and drinking
- Whether pain makes lying flat difficult
What to bring
- The prescription, with the clinical indication written on it
- The pancreatic protocol or triphasic CT — films and report. This is the study the PET is read alongside
- EUS and ERCP reports
- Biopsy and histopathology reports
- Previous PET, CT and MRI scans
- CA 19-9 results over time, if these have been followed
- Recent blood reports including bilirubin and kidney function
- A list of current medications
- Insurance or reimbursement papers, if you plan to file a claim
- Photo identification
Reading the report
A pancreatic PET report describes the primary lesion, then the regional nodes, the liver, the peritoneal surfaces, and then the rest of the body.
Liver and peritoneum are the areas that most often change the plan, because disease there generally means surgery is not the answer.
SUVmax measures tracer accumulation adjusted for dose and weight. In the pancreas particularly, remember that pancreatitis raises it and stromal-rich tumours may show modest uptake. It is not a cancer score, and it does not distinguish inflammation from malignancy.
Vessel involvement will generally be described from the CT component, but the definitive assessment comes from the dedicated pancreatic protocol CT rather than the PET.
The impression is the reporting physician’s summary and the part your surgeon or oncologist reads first.
Radiation and safety
A PET CT involves ionising radiation from the tracer and the CT component, which is why it is ordered for specific clinical questions rather than routinely. Fluorine-18 has a half-life of under two hours; Gallium-68 is faster still at around 68 minutes. Essentially none remains active by the following day.
Precautions afterwards are simple and temporary: drink water as far as you are able, and keep some distance from pregnant women and young children for the rest of the day.
If you are pregnant, breastfeeding or might be pregnant, raise it before the scan is scheduled.
What decides the cost
The tracer matters here more than usual, and each one is listed separately — FDG whole body Rs 7,999, DOTANOC Rs 19,999, FAPI Rs 21,999, Exendin Rs 25,999. Each figure includes the scan, the tracer and the reporting, and nothing is added at the counter.
An FDG study and a 68Ga FAPI or DOTANOC study are different procedures with different production requirements. Whether contrast is used, whether the study is whole body, and the clinical indication all affect the figure as well.
If your team has also asked for a pancreatic protocol CT, that is a separate investigation with its own cost — worth clarifying early. Our CT rates, including triphasic studies, are published openly on our CT page.
Contrast or additional views are occasionally required by the protocol, so send the prescription and we will confirm the complete figure for your exact study in writing, before you book.
Ask these before you book
- Is the tracer included in the figure you quoted? Particularly important if FAPI or DOTANOC has been prescribed.
- Is my prescribed tracer available, and on which date?
- Is contrast included, if my protocol requires it?
- Is reporting included?
- What is the total I will pay at the counter? In writing.
- Will my pancreatic protocol CT be taken into account?
- Can preparation be adapted for jaundice, poor intake or unstable blood sugar?
- When will the report be ready, and can it be before my surgical appointment on [date]?
Where Neurad fits
Neurad Diagnostic and Healthcare LLP is a dedicated PET-CT and nuclear medicine centre at B-3, opposite Metro Pillar No. 233, near Paschim Vihar West Metro Station, New Multan Nagar, Paschim Vihar, New Delhi-110056. Monday to Saturday, 8:00 AM to 5:00 PM.
An in-house 68Ga generator — so FAPI, DOTANOC, Exendin and PSMA studies are produced on site and scheduled on working days rather than held until an outside supply is arranged. In pancreatic disease, where FAPI and DOTANOC are both frequently the appropriate tracers, this matters more than in most cancers.
Triphasic and multiphasic CT available, relevant where liver lesions need characterising alongside the metabolic assessment.
Reported by our own nuclear medicine team, not outsourced.
Your pancreatic protocol CT and previous imaging taken into account, provided you bring them.
Written preparation instructions adapted for jaundice, stents, poor oral intake and unstable blood sugar — tell us at booking and you will get instructions written for your situation rather than a generic sheet.
Blood sugar checked before injection as standard, with diabetic patients planned in advance.
Image-guided FNAC and CT-guided biopsy available, so where tissue confirmation is needed it can often be arranged without another centre and another journey.
Complimentary pickup and drop within 3 km; beyond that, Rs 50 per km.
The all-inclusive figure in writing before you book.
Frequently asked questions
Why do I need a CT if I am having a PET?
Because they answer different questions. The pancreatic protocol CT determines whether the tumour can be surgically removed, which depends on its relationship to major blood vessels — a millimetre question about anatomy. PET assesses metabolic activity and surveys the body for distant disease.
Can a PET scan tell whether it is cancer or pancreatitis?
Not reliably on its own. Chronic and autoimmune pancreatitis both take up FDG and can closely resemble malignancy. This is why tissue sampling is frequently needed and why your history of pancreatitis, alcohol use or autoimmune disease should be mentioned.
Why has my doctor asked for a FAPI scan instead of FDG?
Pancreatic tumours often have a dense fibrous stroma and relatively low cellular density, which can make FDG uptake modest. FAPI targets that stroma directly, and normal liver and bowel show relatively low FAPI uptake, which helps when looking for liver or peritoneal disease.
Why do some centres make me wait for a FAPI scan?
FAPI is built on Gallium-68, whose half-life is roughly 68 minutes. It cannot be shipped from a distant facility and must be produced close to the patient on the day. Centres without their own generator arrange supply on particular days.
My tumour is a neuroendocrine tumour. Is FDG right?
Usually not as the primary study. Well-differentiated pancreatic neuroendocrine tumours typically express somatostatin receptors, which DOTANOC targets — and DOTANOC also assesses suitability for PRRT. Sometimes both DOTANOC and FDG are requested deliberately.
I have a biliary stent. Does that affect the scan?
Stent placement causes local inflammation that takes up the tracer, and cholangitis produces intense uptake. Always mention the stent, the date it was placed, and any fever or chills.
I am jaundiced and eating very little. How do I fast?
Tell the centre at booking rather than following generic instructions. Dehydration and unstable blood sugar both need planning when oral intake is poor.
My blood sugar has become difficult to control recently. Does that matter?
Yes. Circulating glucose competes with FDG and degrades image quality. New-onset or unstable diabetes is also common in pancreatic disease. Mention it at booking so timing can be planned.
Can PET detect small peritoneal deposits?
Larger ones, yes. Very small deposits fall below reliable detection on any scan, which is why laparoscopy is sometimes used before major surgery where peritoneal disease is a concern.
Why should I bring old scans?
Because a pancreatic abnormality unchanged for years reads very differently from one that appeared in six months. In a region where inflammation mimics malignancy, that history is valuable.
Pain makes it hard for me to lie flat. Can I still have the scan?
Yes, but say so before you are positioned. Adjustments are possible, and discomfort causes movement which degrades the images.
What does a pancreatic PET CT cost?
It depends on the tracer: FDG whole body is Rs 7,999, 68Ga DOTANOC Rs 19,999, 68Ga FAPI Rs 21,999 and 68Ga Exendin Rs 25,999, each all-inclusive of scan, tracer and reporting. Send the prescription on WhatsApp and we will share the all-inclusive figure for your exact study before you book.
Do I need a prescription?
Yes. A valid prescription is required for all PET CT studies, and it should state the clinical indication and the tracer.
Related reading
- Triple phase PET CT explained — the multiphasic liver protocol
- PET CT for colorectal cancer — liver metastases and assessment before surgery
- FDG PET scan cost — and when FDG is the wrong tracer for your case
- PET CT scan price in Delhi — what decides your figure, and the nine questions to ask
Booking your scan
Send a photograph of the prescription to 8368225620 on WhatsApp. Include four things: whether you are diabetic and what you take, whether you are jaundiced or have a stent and when it was placed, how much you are able to eat and drink, and the date of your next surgical or oncology appointment.
You will get the all-inclusive rate, confirmation of tracer availability and a slot, preparation instructions written for your situation, and a note on which imaging to carry — the pancreatic protocol CT in particular.
Prefer to speak to someone? Call 8368225620 or 7011968879, Monday to Saturday, 8:00 AM to 5:00 PM.
This page is general information about the role of PET CT in pancreatic disease. It is not medical advice and must not be used to interpret your own report or to decide for or against a scan or an operation. Which tracer and which study you need is a clinical decision made by your treating team, who read imaging alongside pathology, blood results and your clinical condition. A valid prescription is required for all PET CT studies.
